Immunas
About Immunas
Immunas develops a point-of-care diagnostic device that within minutes will be able to determine if the source of infection is bacterial or viral. This will lead to informed antibiotic treatment decisions and reduce the number of avoidable deaths in societies due to antimicrobial resistance. Immunas is a med-tech start-up aiming to develop a rapid test allowing doctors to accurately distinguish the sources of infection. The test reduces antibiotic overuse and helps minimize antibiotic resistance. Patients receive optimal treatment faster with the test. Unlike traditional procedures that take hours to days to complete, Immunas' cutting edge chip-based technology, within minutes, will be able to accurately determine whether the cause of infection is bacterial or viral. Together with cost-effectiveness, ease-of-use, minimal invasiveness for the patient and immense potential impact on pressing public health concerns, we genuinely hope to enable smart and responsible use of antibiotics for the benefits of patients and for societies at large.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Total funding: $10.2K
- Last round: Grant (Aug 2016)
Canonical: https://fsome.com/organization/immunas-2741686 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.